

## Disclosure of total number of voting rights and number of shares in the capital as of January 31<sup>st</sup>, 2025

Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.

Total number of shares	<b>18,631,386</b>
Number of real voting rights* (excluding treasury shares**)	<b>18,567,201</b>
Theoretical number of voting rights* (including treasury shares**)	<b>18,608,186</b>

(\*) Class E preference shares are non-voting

(\*\*) pursuant to article 223-11 of the AMF’s General Regulations



**About Median Technologies:** Pioneering innovative imaging services and software as a medical device, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit [www.mediantechnologies.com](http://www.mediantechnologies.com).

### Contacts

#### Median Technologies

Emmanuelle Leygues  
VP, Corporate Marketing & Financial  
Communications  
+33 6 10 93 58 88  
[emmanuelle.leygues@mediantechnologies.com](mailto:emmanuelle.leygues@mediantechnologies.com)

#### Press - ALIZE RP

Caroline Carmagnol  
+33 6 64 18 99 59  
[median@alizerp.com](mailto:median@alizerp.com)

#### Investors - ACTIFIN

Ghislaine Gasparetto  
+33 6 21 10 49 24  
[ghislaine.gasparetto@seitosei-actifin.com](mailto:ghislaine.gasparetto@seitosei-actifin.com)